Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice
Background Treatments for pancreatic ductal adenocarcinoma are poorly effective, at least partly due to the tumor’s immune-suppressive stromal compartment. New evidence of positive effects on immune responses in the tumor microenvironment (TME), compelled us to test the combination of gemcitabine (G...
Saved in:
| Main Authors: | Ilse Rooman, Claudia Gravekamp, Lydie Meheus, Amanda Beck, Benson Chellakkan Selvanesan, Kiran Meena, Olaya Lara |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001250.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer
by: Carlo Lazzaro
Published: (2024-12-01) -
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01) -
De novo biosynthesis and nicotinamide biotransformation of nicotinamide mononucleotide by engineered yeast cells
by: Yanna Ren, et al.
Published: (2024-11-01) -
Adjuvant 5‐fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer
by: Minoru Kitago, et al.
Published: (2024-07-01) -
Oncolytic influenza virus enhances killing effect of gemcitabine against pancreatic cancer cells
by: MENG Zihe, et al.
Published: (2025-01-01)